Navigation Links
Why 'lazy Susan' has a weak heart
Date:3/5/2009

When young, apparently healthy athletes suddenly collapse, it can be due to hereditary cardiac disease. Researchers at the Heidelberg University Hospital have now discovered a genetic modification that leads to cardiac weakness in an animal model. Just one "false" amino acid can give zebrafish a heart condition. Since the fish have a genetic makeup similar to that of humans, these defects could be critical for humans as well.

Cardiac insufficiency is not just a disease that results from a heart attack or myocarditis. For young people in particular there is often an underlying genetic cause (cardiomyopathy). Some 30,000 people in Germany are affected and the disease often remains undetected for a long time. The tragic cases of athletes who suddenly collapse during training or competition are well known. The cardiology department at the Heidelberg University Hospital (Medical Director Prof. Hugo Katus) is one of the major centers in Germany for the treatment and research of cardiac insufficiency.

For many years, the researchers in Heidelberg have been studying the zebrafish. The genetic variant that suffers from cardiomyopathy is called "Lazy Susan" and got its nickname because of its slow blood flow. Dr. Benjamin Meder and Christina Laufer from Dr. Wolfgang Rottbauer's research group (Department of Cardiology) examined its muscle protein myosin light chain-1, which is involved in contraction of the heart muscle. They discovered the crucial change in the amino acid Serine 195, which was lost through mutation. This single change is sufficient to severely limit heart function.

Some 70 percent of the genes of zebrafish and humans are identical

Can these research results be transferred from zebrafish to humans? In the next step, the Heidelberg cardiologists plan to search for the same mutation in patients' genes. Since approximately 70 percent of human genes are identical with those of zebrafish, the researchers are confident that a Serine 195 mutation will have a similar affect in human hearts. The researchers also hope to develop new therapies for patients. A targeted modification of the amino acid Serine could increase the activity of the actin-myosin complex and result in an increase of cardiac contractility.


'/>"/>

Contact: Dr. Benjamin Meder
Benjamin.Meder@med.uni-heidelberg.de
062-215-64835
University Hospital Heidelberg
Source:Eurekalert

Related biology news :

1. Type 1 diabetes triggered by lazy regulatory T-cells: McGill researchers
2. Abnormal fat metabolism underlies heart problems in diabetic patients
3. High blood pressure, low energy -- a recipe for heart failure
4. Human derived stem cells can repair rat hearts damaged by heart attack
5. Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
6. Heart of Herschel to be presented to media
7. Minimally invasive heart surgery research wins NIH award
8. A step toward tissue-engineered heart structures for children
9. Research explains link between cholesterol and heart disease
10. Eating competence may lower risk of heart disease
11. Cardiologists and heart surgeons meet for Controversies and Advances conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will be ... at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December ... clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the ...
(Date:12/2/2016)... ... 2016 , ... DrugDev believes the only way to achieve real ... All three tenets were on display at the 2nd Annual DrugDev User Summit (hosted ... CRO and site organizations to discuss innovation and the future of clinical research. ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 ... Billion by 2021, growing at a CAGR of 7.3% during the ... segment while hospitals and diagnostic laboratories segment accounted for the largest ... ... Complete report on global immunohistochemistry (IHC) market spread across 225 ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
Breaking Biology Technology: